Management strategies for patients with pulmonary hypertension in the intensive care unit

Critical Care Medicine

Volumn 35, Issue 9, 2007, Pages 2037-2050

  Zamanian, Roham T ^a   Haddad, Francois ^a   Doyle, Ramona L ^b   Weinacker, Ann B ^a,c  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

Dobutamine; Intensive care unit; Nitric oxide; Prostacyclin; Pulmonary hypertension; Right ventricular failure; Vasopressor agents

Indexed keywords

ADRENALIN; ANTICOAGULANT AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; ISOPRENALINE; MILRINONE; NESIRITIDE; NIFEDIPINE; NITRIC OXIDE; NORADRENALIN; PHENYLEPHRINE; PROSTACYCLIN; PROSTAGLANDIN E; PROSTAGLANDIN E1; SILDENAFIL; UNIPROST; VASOPRESSIN; ZAPRINAST;

ARTIFICIAL VENTILATION; CHRONIC LIVER DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CRITICAL ILLNESS; DIARRHEA; DRUG DOSE TITRATION; DRUG INDUCED HEADACHE; HEART RIGHT VENTRICLE FAILURE; HUMAN; HYPOTENSION; INTENSIVE CARE UNIT; LOADING DRUG DOSE; LUNG EMBOLISM; MEDLINE; MITRAL VALVE STENOSIS; MONOTHERAPY; NAUSEA; NONHUMAN; OPTIMAL DRUG DOSE; OXYGEN THERAPY; PATHOGENESIS; PHYSIOLOGY; POSTOPERATIVE COMPLICATION; PREGNANCY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; VEIN OCCLUSION; VOMITING;

EID: 34548200760     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000280433.74246.9E     Document Type: Article

References (163)

1. Hoeper MM, Galiè N, Murali S, et al: Outcome after cardiopulmonary resuscitation in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2002; 165:341-344
2. Rubin LJ: Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126:7S-10S
3. Chemla D, Castelain V, Herve P, et al: Haemodynamic evaluation of pulmonary hypertension. Eur Respir J 2002; 20:1314-1331
4. Barst RJ, McGoon M, Torbicki A, et al: Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43:40S-47S
5. Humbert M, Morrell NW, Archer SL, et al: Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43:13S-24S
6. Humbert M, Sitbon O, Simonneau G: Therapies for pulmonary arterial hypertension. N Engl J Med 2004; 351:1425-1436
7. Weitzenblum E, Chaouat A: Pulmonary hypertension due to chronic hypoxic lung disease. In: Peacock AJ, Rubin LJ (Eds). Pulmonary Circulation: Diseases and Their Treatment. Second Edition. New York, NY, Oxford University Press, 2004, pp 376
8. Ishikawa S, Miyauchi T, Sakai S, et al: Elevated levels of plasma endothelin-1 in young patients with pulmonary hypertension caused by congenital heart disease are decreased after successful surgical repair. J Thorac Cardiovasc Surg 1995; 110:271-273
9. Stewart DJ, Levy RD, Cernacek P, et al: Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease? Ann Intern Med 1991; 114:464-469
10. Kim H, Yung GL, Marsh JJ, et al: Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension. Eur Respir J 2000; 15:640-648
11. Herve P, Launay JM, Scrobohaci ML, et al: Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995; 99:249-254
12. Egermayer P, Town GI, Peacock AJ: Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension. Thorax 1999; 54:161-168
13. Abenhaim L, Moride Y, Brenot F, et al: Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 335:609-616
14. Machado RD, Koehler R, Glissmeyer E, et al: Genetic association of the serotonin transporter in pulmonary arterial hypertension. Am J Resp Crit Care Med 2006; 173:793-797
15. Nath J, Foster E, Heidenreich PA: Impact of tricuspid regurgitation on long-term survival. J Am Coll Cardiol 2004; 43:405-409
16. Chin KM, Kim NH, Rubin LJ: The right ventricle in pulmonary hypertension. Coron Artery Dis 2005; 16:13-18
17. Dell'Italia LJ: The right ventricle: Anatomy, physiology, and clinical importance. Curr Probl Cardiol 1991; 16:653-720
18. Charloux A, Chaouat A, Piquard F, et al: Renal hyporesponsiveness to brain natriuretic peptide: Both generation and renal activity of cGMP are decreased in patients with pulmonary hypertension. Peptides 2006; 27:2993-2999
19. Klinger JR, Thaker S, Houtchens J, et al: Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with pulmonary arterial hypertension. Chest 2006; 129:417-425
20. Bates B, Bickley LS, Hoekelman RA: A guide to physical examination and history taking, Sixth Edition. Philadelphia, Lippincott; 1995
21. Mehta NJ, Jani K, Khan IA: Clinical usefulness and prognostic value of elevated cardiac troponin I levels in acute pulmonary embolism. Am Heart J 2003; 145:821- 825
22. La Vecchia L, Ottani F, Favero L, et al: Increased cardiac troponin I on admission predicts in-hospital mortality in acute pulmonary embolism. Heart 2004; 90:633-637
23. Leuchte HH, Holzapfel M, Baumgartner RA, et al: Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol 2004; 43:764-770
24. Berendes E, Van Aken H, Raufhake C, et al: Differential secretion of atrial and brain natriuretic peptide in critically ill patients. Anesth Analg 2001; 93:676-682
25. Tung RH, Garcia C, Morss AM, et al: Utility of B-type natriuretic peptide for the evaluation of intensive care unit shock. Crit Care Med 2004; 32:1643-1647
26. McLean AS, Huang SJ, Nalos M, et al: The confounding effects of age, gender, serum creatinine, and electrolyte concentrations on plasma B-type natriuretic peptide concentrations in critically ill patients. Crit Care Med 2003; 31:2611-2618
27. McLean AS, Tang B, Nalos M, et al: Increased B-type natriuretic peptide (BNP) level is a strong predictor for cardiac dysfunction in intensive care unit patients. Anaesth Intensive Care 2003; 31:21-27
28. Takami Y, Horio T, Iwashima Y, et al: Diagnostic and prognostic value of plasma brain natriuretic peptide in non- dialysis-dependent CRF. Am J Kidney Dis 2004; 44:420-428
29. McCullough PA, Sandberg KR: B-type natriuretic peptide and renal disease. Heart Fail Rev 2003; 8:355-358
30. Maeder M, Fehr T, Rickli H, et al: Sepsis-associated myocardial dysfunction: Diagnostic and prognostic impact of cardiac troponins and natriuretic peptides. Chest 2006; 129:1349-1366
31. Murphy ML, Thenabadu PN, de Soyza N, et al: Reevaluation of electrocardiographic criteria for left, right, and combined cardiac ventricular hypertrophy. Am J Cardiol 1984; 53:1140-1147
32. Bossone E, Paciocco G, Iarussi D, et al: The prognostic role of the ECG in primary pulmonary hypertension. Chest 2002; 121:513-518
33. Iles S, Le Heron CJ, Davies G, et al: ECG score predicts those with the greatest percentage of perfusion defects due to acute pulmonary thromboembolic disease. Chest 2004; 125:1651-1656
34. Vieillard-Baron A, Prin S, Chergui K, et al: Echo-Doppler demonstration of acute cor pulmonale at the bedside in the medical intensive care unit. Am J Respir Crit Care Med 2002; 166:1310-1319
35. Jardin F, Vieillard-Baron A: Monitoring of right-sided heart function. Curr Opin Crit Care 2005; 11:271-279
36. McConnell MV, Solomon SD, Rayan ME, et al: Regional right ventricular dysfunction detected by echocardiography in acute pulmonary embolism. Am J Cardiol 1996; 78:469-473
37. Raymond RJ, Hinderliter AL, Willis PW, et al: Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 2002; 39:1214-1219
38. Daniels LB, Krummen DE, Blanchard DG: Echocardiography in pulmonary vascular disease. Cardiol Clin 2004; 22:383-399
39. Karski JM: Transesophageal echocardiography in the intensive care unit. Semin Cardiothorac Vasc Anesth 2006; 10:162-166
40. Badesch DB, Abman SH, Ahearn GS, et al: Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126:35S-62S
41. McLaughlin VV, Presberg KW, Doyle RL, et al: Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126:78S-92S
42. Cigarroa RG, Lange RA, Williams RH, et al: Underestimation of cardiac output by thermodilution in patients with tricuspid regurgitation. Am J Med 1989; 86:417-420
43. Caruso LJ, Layon AJ, Gabrielli A: What is the best way to measure cardiac output? Who cares, anyway? Chest 2002; 122:771-774
44. Thabut G, Dauriat G, Stern JB, et al: Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 2005; 127:1531-1536
45. Chin KM, Kim NH, Rubin LJ: The right ventricle in pulmonary hypertension. Coron Artery Dis 2005; 16:13-18
46. Goldstein JA, Harada A, Yagi Y, et al: Hemodynamic importance of systolic ventricular interaction, augmented right atrial contractility, and atrioventricular synchrony in acute right ventricular dysfunction. J Am Coll Cardiol 1990; 16:181-189
47. Olsson JK, Zamanian RT, Feinstein JA, et al: Surgical and interventional therapies for pulmonary arterial hypertension. Semin Respir Crit Care Med 2005; 26:417-428
48. Miro AM, Pinsky MR: Heart-lung interactions. In: Tobin MJ (Ed). Principles and Practice of Mechanical Ventilation. New York, NY, McGraw-Hill, 1994, pp 647-672
49. Artucio H, Hurtado J, Zimet L, et al: PEEP-induced tricuspid regurgitation. Intensive Care Med 1997; 23:836-840
50. Jardin F, Vieillard-Baron A: Right ventricular function and positive pressure ventilation in clinical practice: From hemodynamic subsets to respirator settings. Intensive Care Med 2003; 29:1426-1434
51. Carvalho CRR, Barbas CSV, Medeiros DM, et al: Temporal hemodynamic effects of permissive hypercapnia associated with ideal PEEP in ARDS. Am J Respir Crit Care Med 1997; 156:1458-1466
52. Viitanen A, Salmenpera M, Heinonen J: Right ventricular response to hypercarbia after cardiac surgery. Anesthesiology 1990; 73:393-400
53. Balanos GM, Talbot NP, Dorrington KL, et al: Human pulmonary vascular response to 4 h of hypercapnia and hypocapnia measured using Doppler echocardiography. J Appl Physiol 2003; 94:1543-1551
54. Leier CV, Webel J, Bush CA: The cardiovascular effects of the continuous infusion of dobutamine in patients with severe cardiac failure. Circulation 1977; 56:468-472
55. Kerbaul F, Rondelet B, Motte S, et al: Effects of norepinephrine and dobutamine on pressure load-induced right ventricular failure. Crit Care Med 2004; 32:1035-1040
56. Bradford KK, Deb B, Pearl RG: Combination therapy with inhaled nitric oxide and intravenous dobutamine during pulmonary hypertension in the rabbit. J Cardiovasc Pharmacol 2000; 36:146-151
57. Steendijk P: Right ventricular function and failure: Methods, models, and mechanisms. Crit Care Med 2004; 32:1087-1089
58. Vizza CD, Rocca GD, Roma AD, et al: Acute hemodynamic effects of inhaled nitric oxide, dobutamine, and a combination of the two in patients with mild to moderate secondary pulmonary hypertension. Crit Care 2001; 5:355-361
59. Kwak YL, Lee CS, Park YH, et al: The effect of phenylephrine and norepinephrine in patients with chronic pulmonary hypertension*. Anaesthesia 2002; 57:9-14
60. Ducas J, Duval D, Dasilva H, et al: Treatment of canine pulmonary hypertension: Effects of norepinephrine and isoproterenol on pulmonary vascular pressure-flow characteristics. Circulation 1987; 75:235-242
61. Tritapepe L, Voci P, Cogliati AA, et al: Successful weaning from cardiopulmonary bypass with central venous prostaglandin E1 and left atrial norepinephrine infusion in patients with acute pulmonary hypertension. Crit Care Med 1999; 27:2180-2183
62. Lollgen H, Drexler H: Use of inotropes in the critical care setting. Crit Care Med 1990; 18:S56-S60
63. Ducas J, Stitz M, Gu S, et al: Pulmonary vascular pressure-flow characteristics. Effects of dopamine before and after pulmonary embolism. Am Rev Respir Dis 1992; 146:307-312
64. Holloway EL, Polumbo RA, Harrison DC: Acute circulatory effects of dopamine in patients with pulmonary hypertension. Br Heart J 1975; 37:482-485
65. Rich S, Gubin S, Hart K: The effects of phenylephrine on right ventricular performance in patients with pulmonary hypertension. Chest 1990; 98:1102-1106
66. Tisdale JE, Patel RV, Webb CR, et al: Proarrhythmic effects of intravenous vasopressors. Ann Pharmacother 1995; 29:269-281
67. Prielipp RC, McLean R, Rosenthal MH, et al: Hemodynamic profiles of prostaglandin E1, isoproterenol, prostacyclin, and nifedipine in experimental porcine pulmonary hypertension. Crit Care Med 1991; 19:60-67
68. Garcia-Villalon AL, Garcia JL, Fernandez N, et al: Regional differences in the arterial response to vasopressin: Role of endothelial nitric oxide. Br J Pharmacol 1996; 118:1848-1854
69. Evora PR, Pearson PJ, Schaff HV: Arginine vasopressin induces endothelium-dependent vasodilatation of the pulmonary artery. V1-receptor-mediated production of nitric oxide. Chest 1993; 103:1241-1245
70. Sai Y, Okamura T, Amakata Y, et al: Comparison of responses of canine pulmonary artery and vein to angiotensin II, bradykinin, and vasopressin. Eur J Pharmacol 1995; 282:235-241
71. Leather HA, Segers P, Berends N, et al: Effects of vasopressin on right ventricular function in an experimental model of acute pulmonary hypertension. Crit Care Med 2002; 30:2548-2552
72. Tsuneyoshi I, Yamada H, Kakihana Y, et al: Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med 2001; 29:487-493
73. Rossaint R, Gerlach H, Schmidt-Ruhnke H, et al: Efficacy of inhaled nitric oxide in patients with severe ARDS. Chest 1995; 107:1107-1115
74. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, et al: Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 1991; 338:1173-1174
75. Semigran MJ, Cockrill BA, Kacmarek R, et al: Hemodynamic effects of inhaled nitric oxide in heart failure. J Am Coll Cardiol 1994; 24:982-988
76. Girard C, Lehot JJ, Pannetier JC, et al: Inhaled nitric oxide after mitral valve replacement in patients with chronic pulmonary artery hypertension. Anesthesiology 1992; 77:880-883
77. Hart CM: Nitric oxide in adult lung disease. Chest 1999; 115:1407-1417
78. Kaisers U, Busch T, Deja M, et al: Selective pulmonary vasodilation in acute respiratory distress syndrome. Crit Care Med 2003; 31:S337-S342
79. Taylor RW, Zimmerman JL, Dellinger RP, et al: Low-dose inhaled nitric oxide in patients with acute lung injury: A randomized controlled trial. JAMA 2004; 291:1603-1609
80. Cockrill BA, Kacmarek RM, Fifer MA, et al: Comparison of the effects of nitric oxide, nitroprusside, and nifedipine on hemodynamics and right ventricular contractility in patients with chronic pulmonary hypertension. Chest 2001; 119:128-136
81. Bhorade S, Christenson J, O'Connor M, et al: Response to inhaled nitric oxide in patients with acute right heart syndrome. Am J Respir Crit Care Med 1999; 159:571-579
82. Weinberger B, Laskin DL, Heck DE, et al: The toxicology of inhaled nitric oxide. Toxicol Sci 2001; 59:5-16
83. Wang T, El Kebir D, Blaise G: Inhaled nitric oxide in 2003: A review of its mechanisms of action. Can J Anaesth 2003; 50:839-846
84. Christenson J, Lavoie A, O'Connor M, et al: The incidence and pathogenesis of cardiopulmonary deterioration after abrupt withdrawal of inhaled nitric oxide. Am J Respir Crit Care Med 2000; 161:1443-1449
85. McLaughlin VV, Genthner DE, Panella MM, et al: Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998; 338:273-277
86. McLaughlin VV, Shillington A, Rich S: Survival in primary pulmonary hypertension: The impact of epoprostenol therapy. Circulation 2002; 106:1477-1482
87. Badesch DB, Tapson VF, McGoon MD, et al: Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000; 132:425-434
88. Barst RJ, Rubin LJ, Long WA, et al: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334:296-302
89. Hache M, Denault AY, Belisle S, et al: Inhaled prostacyclin (PGI2) is an effective addition to the treatment of pulmonary hypertension and hypoxia in the operating room and intensive care unit. Can J Anaesth 2001; 48:924-929
90. De Wet CJ, Affleck DG, Jacobsohn E, et al: Inhaled prostacyclin is safe, effective, and affordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgery. J Thorac Cardiovasc Surg 2004; 127:1058-1067
91. Gessler T, Schmehl T, Hoeper MM, et al: Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension. Eur Respir J 2001; 17:14-19
92. Hoeper MM, Schwarze M, Ehlerding S, et al: Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000; 342:1866-1870
93. Hoeper MM, Olschewski H, Ghofrani HA, et al: A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. J Am Coll Cardiol 2000; 35:176-182
94. Deb B, Bradford K, Pearl RG: Additive effects of inhaled nitric oxide and intravenous milrinone in experimental pulmonary hypertension. Crit Care Med 2000; 28:795-799
95. Chen EP, Bittner HB, Davis RD Jr, et al: Milrinone improves pulmonary hemodynamics and right ventricular function in chronic pulmonary hypertension. Ann Thorac Surg 1997; 63:814-821
96. Khazin V, Kaufman Y, Zabeeda D, et al: Milrinone and nitric oxide: Combined effect on pulmonary artery pressures after cardiopulmonary bypass in children. J Cardiothorac Vasc Anesth 2004; 18:156-159
97. Matot I, Gozal Y: Pulmonary responses to selective phosphodiesterase-5 and phosphodiesterase-3 inhibitors. Chest 2004; 125:644-651
98. Lepore JJ, Maroo A, Pereira NL, et al: Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. Am J Cardiol 2002; 90:677-680
99. Bhatia S, Frantz RP, Severson CJ, et al: Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. Mayo Clin Proc 2003; 78:1207-1213
100. Michelakis E, Tymchak W, Lien D, et al: Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: Comparison with inhaled nitric oxide. Circulation 2002; 105:2398-2403
101. Trachte AL, Lobato EB, Urdaneta F, et al: Oral sildenafil reduces pulmonary hypertension after cardiac surgery. Ann Thorac Surg 2005; 79:194-197
102. Krowka MJ, Mandell MS, Ramsay MA, et al: Hepatopulmonary syndrome and portopulmonary hypertension: A report of the multicenter liver transplant data base. Liver Transplantation 2004; 10:174-182
103. Rafanan AL, Maurer J, Mehta AC, et al: Progressive portopulmonary hypertension after liver transplantation treated with epoprostenol. Chest 2000; 188:1497-1500
104. Mikhail GW, Prasad SK, Li W, et al: Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: Acute and midterm effects. Eur Heart J 2004; 25:431-436
105. Lepore JJ, Maroo A, Bigatello LM, et al: Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: Combined administration with inhaled nitric oxide. Chest 2005; 127:1647-1653
106. Preston IR, Klinger JR, Houtches J, et al: Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertension. Respir Med 2005; 99:1501-1510
107. Thusu KG, Morin FC, Russell JA, et al: The cGMP phosphodiesterase inhibitor zaprinast enhances the effect of nitric oxide. Am J Respir Crit Care Med 1995; 152:1605-1610
108. Nagamine J, Hill LL, Pearl RG: Combined therapy with zaprinast and inhaled nitric oxide abolishes hypoxic pulmonary hypertension. Crit Care Med 2000; 28:2420-2424
109. Ghofrani HA, Wiedemann R, Rose F, et al: Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002; 136:515-522
110. Ng J, Finney SJ, Shulman R, et al: Treatment of pulmonary hypertension in the general adult intensive care unit: A role for oral sildenafil? Br J Anaesth 2005; 94:774-777
111. Atz AM, Wessel DL: Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology 1999; 91:307-310
112. Fung E, Fiscus RR, Yim A, et al: The potential use of type-5 phosphodiesterase inhibitors in coronary artery bypass graft surgery. Chest 2005; 128:3065-3073
113. O'dell KM, Kalus JS, Kucukarslan S, et al: Nesiritide for secondary pulmonary hypertension in patients with end-stage heart failure. Am J Health-Syst Pharm 2005; 62:606-609
114. Yancy CW: Treatment with B-type natriuretic peptide for chronic decompensated heart failure: Insights learned from the follow-up serial infusion of nesiritide (FUSION) trial. Heart Fail Rev 2004; 9:209-216
115. Roberts DH, Lepore JJ, Maroo A, et al: Oxygen therapy improves cardiac index and pulmonary vascular resistance in patients with pulmonary hypertension. Chest 2001; 120:1547-1555
116. Moloney ED, Evans TW: Pathophysiology and pharmacological treatment of pulmonary hypertension in acute respiratory distress syndrome. Eur Respir J 2003; 21:720-727
117. Magid JH, Manohar M, Goetz TE, et al: Pulmonary vascular pressures of thorough-bred horses exercised 1, 2, 3, and 4 h after furosemide administration. J Vet Pharmacol Ther 2000; 23:81-89
118. Rich S, Seidlitz M, Dodin E, et al: The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest 1998; 114:787-792
119. Buller HR, Agnelli G, Hull RD, et al: Antithrombotic therapy for venous thromboembolic disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:401S-428S
120. Dhainaut JF, Laterre PF, LaRosa SP, et al: The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): Role, methodology, and results. Crit Care Med 2003; 31:2291-2301
121. Laterre PF, Wittebole X, Dhainaut JF: Anticoagulant therapy in acute lung injury. Crit Care Med 2003; 31:S329-S336
122. Glanville AR, Burke CM, Theodore J, et al: Primary pulmonary hypertension. Length of survival in patients referred for heart-lung transplantation. Chest 1987; 91:675-681
123. Young D, Mark H: Fate of the patient with the Eisenmenger syndrome. Am J Cardiol 1971; 28:658-669
124. Hopkins WE, Ochoa LL, Richardson GW, et al: Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant 1996; 15:105
125. Reichenberger F, Pepke-Zaba J, McNeil K, et al: Atrial septostomy in the treatment of severe pulmonary arterial hypertension. Thorax 2003; 58:797-800
126. Sandoval J, Gaspar J, Pulido T, et al: Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment. J Am Coll Cardiol 1998; 32:297-304
127. Rothman A, Sklansky MS, Lucas VW, et al: Atrial septostomy as a bridge to lung transplantation in patients with severe pulmonary hypertension. Am J Cardiol 1999; 84:682-686
128. Kapser W, Konstantinides S, Geibel A, et al: Management strategies and determinants of outcome in acute major pulmonary embolism: Results of a multicenter registry. J Am Coll Cardiol 1997; 30:1165-1171
129. Zeni PT, Blank BG, Peeler DW: Use of rheolytic thrombectomy in treatment of acute massive pulmonary embolism. J Vasc Interv Radiol 2003; 14:1511-1515
130. Yoshida M, Inoue I, Kawagoe T, el al: Novel percutaneous catheter thrombectomy in acute massive pulmonary embolism: Rotational bidirectional thrombectomy (ROBOT). Catheter Cardiovasc Interv 2006; 68:112-117
131. Perlroth DJ, Sanders GD, Gould MK: Effectiveness and cost-effectiveness of thrombolysis in submassive pulmonary embolism. Arch Intern Med 2007; 167:74-80
132. Hirsch LJ, Rooney MW, Wat SS, et al: Norepinephrine and phenylephrine effects on right ventricular function in experimental canine pulmonary embolism. Chest 1999; 100:796-801
133. Molloy WD, Lee KY, Girling L, et al: Treatment of shock in a canine model of pulmonary embolism. Am Rev Respir Dis 1984; 130:870-874
134. Szold O, Khoury W, Biderman P, et al: Inhaled nitric oxide improves pulmonary functions following massive pulmonary embolism: A report of four patients and review of literature. Lung 2006; 184:1-5
135. Mahoney PD, Loh E, Blitz LR, et al: Hemodynamic effects of inhaled nitric oxide in women with mitral stenosis and pulmonary hypertension. Am J Cardiol 2001; 87:188-192
136. Kuo PC, Plotkin JS, Johnson LB, et al: Distinctive clinical features of portopulmonary hypertension. Chest 1997; 112:980-986
137. Kuo PC, Johnson LB, Plotkin JS, et al: Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation 1997; 63:604-606
138. Sussman N, Kaza V, Barshes N, et al: Successful liver transplantation following medical management of portopulmonary hypertension: A single-center series. Am J Transplant 2006; 6:2177-2182
139. Tan HP, Markowitz JS, Montgomery RA, et al: Liver transplantation in patients with severe portopulmonary hypertension treated with preoperative chronic intravenous epoprostenol. Liver Transpl 2001; 7:745-749
140. Reichenberger F, Voswinckel R, Steveling E, et al: Sildenafil treatment for portopulmonary hypertension. Eur Respir J 2006; 28:563-567
141. Chua R, Keogh A, Miyashita M: Novel use of sildenafil in the treatment of portopulmonary hypertension. J Heart Lung Transplant 2005; 24:498-500
142. Saner FH, Nadalin S, Pavlakovic G, et al: Portopulmonary hypertension in the early phase following liver transplantation. Transplantation 2006; 82:887-891
143. Ramsay MA: The perioperative management of portopulmonary hypertension with NO and epoprostenol. Anesthesiology 1999; 90:299-301
144. Bernstein AD, Parsonnet V: Bedside estimation of risk as an aid for decision-making in cardiac surgery. Ann Thorac Surg 2000; 69:823-828
145. Ng CS, Wan S, Yim AP, et al: Pulmonary dysfunction after cardiac surgery. Chest 2002; 121:1269-1277
146. Lamarche Y, Malo O, Thorin E, et al: Inhaled but not intravenous milrinone prevents pulmonary endothelial dysfunction after cardiopulmonary bypass. J Thorac Cardiovasc Surg 2005; 130:83-92
147. Fattouch K, Sbraga F, Sampognaro R, et al: Treatment of pulmonary hypertension in patients undergoing cardiac surgery with cardiopulmonary bypass: A randomized, prospective, double-blind study. J Cardiovasc Med (Hagerstown) 2006; 7:119-123
148. Della Rocca G, Coccia C: Nitric oxide in thoracic surgery. Minerva Anestesiol 2005; 71:313-318
149. Fattouch K, Sbraga F, Bianco G, et al: Inhaled prostacyclin, nitric oxide, and nitroprusside in pulmonary hypertension after mitral valve replacement. J Card Surg 2005; 20:171-176
150. Lowson SM, Doctor A, Walsh BK, et al: Inhaled prostacyclin for the treatment of pulmonary hypertension after cardiac surgery. Crit Care Med 2002; 30:2762-2764
151. Stobierska-Dzierzek B, Awad H, Michler RE: The evolving management of acute right-sided heart failure in cardiac transplant recipients. J Am Coll Cardiol 2001; 38:923-931
152. George I: Clinical indications for use and outcomes after iNO therapy. Ann Thorac Surg 2006; 82:2161-2169
153. Ardehali A, Hughes K, Sadeghi A, et al: Inhaled nitric oxide for pulmonary hypertension after heart transplantation. Transplantation 2001; 72:638-641
154. Solina A, Papp D, Ginsberg S, et al: A comparison of inhaled nitric oxide and milrinone for the treatment of pulmonary hypertension in adult cardiac surgery patients. J Cardiothorac Vasc Anesth 2000; 14:12-17
155. Theodoraki K, Rellia P, Thanopoulos A, et al: Inhaled iloprost controls pulmonary hypertension after cardiopulmonary bypass. Can J Anesth 2002; 49:963-967
156. Theodoraki K, Tsiapras D, Tsourelis L, et al: Inhaled iloprost in eight heart transplant recipients presenting with post-bypass acute right ventricular dysfunction. Acta Anaesthesiol Scand 2006; 50:1213-1217
157. Atz AM, Lefler AK, Fairbrother DL, et al: Sildenafil augments the effect of inhaled nitric oxide for postoperative pulmonary hypertension crisis. J Thorac Cardiovasc Surg 2002; 124:628-629
158. Klodell CT, Morey TE, Lobato EB, et al: Effect of sildenafil on pulmonary artery pressure, systemic pressure, and nitric oxide utilization in patients with left ventricular assist devices. Ann Thorac Surg 2007; 83:68-71
159. Al-Khaldi A, Reitz B, Zhu H, et al: Heterotopic heart transplant combined with postoperative sildenafil use for the treatment of restrictive cardiomyopathy Ann Thorac Surg 2006; 81:1505-1507
160. Mandel J, Mark EJ, Hales CA: Pulmonary veno-occlusive disease. Am J Respir Crit Care Med 2000; 162:1964-1973
161. Resten A, Maitre S, Humbert M, et al: Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease. AJR Am J Roentgenol 2004; 183:65-70
162. Budev M, Arroliga A, Emery S: Exacerbation of underlying pulmonary disease in pregnancy. Crit Care Med 2005; 33:S313-S318
163. Segal ES, Valette S, Oster L, et al: Risk management strategies in postmarketing period; safety experience with the US and European bosentan surveillance programmes. Drug Saf 2005; 28:971-980